Search Medical Condition
Please enter condition
Please choose location

Pulmonary Embolism Clinical Trials

A listing of Pulmonary Embolism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (27) clinical trials

The objective of this study is to evaluate the safety and efficacy of the SENTRY IVC Filter

Phase N/A

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

OBJECTIVES: Primary - Determine whether the addition of dalteparin results in improved survival. Secondary - Determine venous thrombotic event-free survival and metastasis-free survival. - Determine serious adverse events in patients treated with this drug. - Determine the toxicity of this drug in these patients. - Determine the quality of life, ...

Phase

Genetic Determinants of Warfarin Anticoagulation Effect

The response to warfarin varies greatly among individuals. Some of this variability can be ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the metabolism of S warfarin. In addition genetic polymorphism in other genes (i.e. VKORC1, factor VII) have been shown to account for some ...

Phase N/A

Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism

Research design: multicenter collaboration, prospective, non-interventional, observational research Research outline: Registration period: Dec 2016 (after ethics committee approval) to May 2018 (1 year and 6 months) Investigation period: Dec 2016 (after ethics committee approval) to Nov 2019 (At least 1 year and 6 months) Target number of participants: 1,000 participants ...

Phase N/A

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

This trial is being conducted to assess the efficacy and safety of recombinant Human Prourokinase in the acute pulmonary embolism.

Phase

Angel Catheter Post Market Registry

The Registry population will include all consecutive patients in whom the Angel® Catheter is placed at participating sites. Information about the use of the catheter will be collected from placement through three days after device removal, or through death or discharge, whichever occurs first. Date of discharge/transfer from the Critical ...

Phase N/A

Randomized Study to Assess the Safety Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

This is a Phase 1b, double-blind (Principal Investigators, study subjects, Sponsor, Academic Research Organization ARO and Clinical Research Organization CRO blinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics PK, and pharmacodynamics PD of DS-1040b in subjects with acute submassive pulmonary embolism.

Phase

Submassive Pulmonary Embolism Experience With EKOS

Previous clinical trials examining thrombolytics used to treat Acute Submassive PE, many times will use fixed dose and duration. Little research has been conducted on the physiologic implication of resolution of symptoms. It seems reasonable, that symptomatic relief results from some degree of hemodynamic normalization. This study will seek to ...

Phase N/A

Early Non-invasive Detection of CTEPH After Pulmonary Embolism

This is a prospective, international, multicenter outcome cohort study. This study starts at the moment patients visit the outpatient clinic 3 to 6 months after a diagnosis of acute PE as part of routine medical care. If patients consent to study participation, the CTEPH clinical prediction score will be calculated. ...

Phase N/A

Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures

Study Design: A prospective, randomised, controlled, single blinded, multi-centre trial. Intervention: After meeting the inclusion criteria stated above and obtaining informed consent, patients will be randomly assigned to three groups: one receiving Nadroparine (2850 IE anti-Xa = 0,3 ml, given once daily), one receiving Fondaparinux (2,5 mg = 0,5 ml, ...

Phase